Glaxo (NYSE: GSK ) and Theravance (NASDAQ: THRX ) start a Phase 3 clinical trial evaluating the safety and efficacy of the "closed" triple combination of FF/UMEC/VI in patients
* And theravance announce initiation of phase iii programme with fixed dose triple combination treatment ff/umec/vi in patients with copd Source text for Eikon: Further company coverage:
Once the market opens, you can track how today's "Stocks To Watch" are performing here . To send in your own ideas for Monday's Stocks To Watch, email email@example.com before 6:00 AM ET Monday. Apple ( AAPL ) – short – Anthony Ruben The Wall Street Journal reports today that China’s
Australia's Therapeutic Goods Administration approves Glaxo ( GSK ) and Theravance 's ( THRX ) Anoro Ellipta (emeclidinium/vilanterol) for the treatment of symptoms in adult patients with chronic obstructive pulmonary
By Options Calling : GlaxoSmithKline ( GSK ) has been undergoing some significant restructuring over the recent past in a bid to cement its position in various core operations. The company has formed key partnerships in the production of various drugs, as it seeks to establish vibrant access to ...
and Welfare approves GlaxoSmithKline ( GSK ) and Theravance 's ( THRX ) Anoro Ellipta ( umeclidinium/vilanterol ) for ..... of the companies' 2002 collaboration agreement, Theravance is obligated to pay Glaxo a milestone payment of
* Press_release:anoro ellipta(umeclidinium/vilant erol) gains approval in Japan for the treatment of COPD
The launch of Anoro (umeclidinium/vilanterol) in the U.K. triggers a $15M milestone payment from Theravance ( THRX ) to GlaxoSmithKline ( GSK ). Anoro is a once-daily bronchodilator for the treatment of symptoms in adults with
* GSK and Theravance announce submission to US regulatory authorities for Fluticasone Furoate/Vilanterol in asthma
the FDA, would potentially mitigate a time-consuming and expensive hurdle for the drug makers in their NDA application efforts. Related tickers: ( CBST -0.6% ) ( NKTR ) ( SLXP +3.2% ) ( THRX -2.4% ) ( PGNX ) Post your comment!